Not a good buy right now for an impatient trader: price is still in a broader downtrend (bearish MA stack), and there are no Intellectia buy signals to override that.
Near-term setup is mixed: the stock is hovering just above key support (~2.37), and options positioning is bullish (low put/call), but the trend needs confirmation (reclaim ~2.52 pivot) before it becomes an attractive momentum entry.
Event backdrop is thin near-term (no recent news), with the next notable scheduled catalyst being earnings on 2026-03-05 (QDEC 2025).
Momentum: MACD histogram slightly positive (0.0012) but positively contracting, suggesting upside momentum is weak/fragile.
RSI(6): 30.5, near oversold (can support a bounce), but not a strong reversal signal by itself.
Key levels: Support S1 ~2.366 (price ~2.41 pre-market slightly above), deeper support S2 ~2.271. Resistance/pivot ~2.518, then R1 ~2.671.
Pattern-based forward look (similar candlesticks): ~60% chance of -0.52% next day, +1.37% next week, +15.98% next month—skews better on a 1-month horizon, but near-term remains choppy.
Volume: Very low put activity (put volume 0; total volume 20), so the bullish read is more about positioning than fresh trading flow.
Volatility: IV30 ~158.6% (IV percentile ~70.9) = elevated uncertainty/expectations; consistent with a speculative biotech profile.
OI/participation: Today’s volume vs 30-day avg ~22.2% (not a “crowded” high-conviction day in options).
Technical Summary
Sell
9
Buy
3
Positive Catalysts
with RSI near oversold—can enable a short-term bounce if buyers defend support.
Neutral/Negative Catalysts
Analyst risk flags: Guggenheim downgrade cited high toxicity and questions on durability/execution risk into future catalysts (e.g., PFS and Phase 3 execution).
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: effectively $0 (no meaningful commercialization yet).
Profitability: Net income -8.50M, worsening YoY (-45.38%); EPS -0.15, also worse YoY (-46.43%).
Overall: continues to be a cash-burn, pre-revenue biotech profile; fundamentals don’t provide near-term support absent clinical/news catalysts.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent direction: sentiment has softened vs earlier optimism.
2025-12-03: Guggenheim downgraded to Neutral from Buy (concerns around toxicity, durability, and execution risk; no PT provided).
2026-01-16: Piper Sandler kept Overweight but cut PT to $8 from $9 (still bullish, but trimming expectations).
Wall Street pros: potential best-in-class EGFR inhibitor thesis + low enterprise value framing.
Wall Street cons: toxicity/durability questions and execution risk around future clinical milestones; mixed coverage implies higher bar for a trend reversal without new data.
Wall Street analysts forecast BDTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDTX is 9 USD with a low forecast of 8 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast BDTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDTX is 9 USD with a low forecast of 8 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.160
Low
8
Averages
9
High
10
Current: 2.160
Low
8
Averages
9
High
10
Piper Sandler
Kelsey Goodwin
Overweight
downgrade
$9 -> $8
AI Analysis
2026-01-16
Reason
Piper Sandler
Kelsey Goodwin
Price Target
$9 -> $8
AI Analysis
2026-01-16
downgrade
Overweight
Reason
Piper Sandler analyst Kelsey Goodwin lowered the firm's price target on Black Diamond Therapeutics to $8 from $9 and keeps an Overweight rating on the shares. Following a flurry of updates from companies across its coverage, the firm updating its 2026 Catalyst Tracker, as well as several models and price targets.
Guggenheim
Brad Canino
Buy -> Neutral
downgrade
2025-12-03
Reason
Guggenheim
Brad Canino
Price Target
2025-12-03
downgrade
Buy -> Neutral
Reason
Guggenheim analyst Brad Canino downgraded Black Diamond Therapeutics to Neutral from Buy.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BDTX
